RT Journal Article
SR Electronic
T1 SARS-CoV-2-specific Humoral Immune Responses after A Single dose of Inactivated Whole-virus SARS-CoV-2 Vaccine in Kidney Transplant Recipients: An Initial Report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260694
DO 10.1101/2021.07.19.21260694
A1 Bruminhent, Jackrapong
A1 Boongird, Sarinya
A1 Assanatham, Montira
A1 Kiertiburanakul, Sasisopin
A1 Malathum, Kumthorn
A1 Nongnuch, Arkom
A1 Phuphuakrat, Angsana
A1 Chaumdee, Pongsathon
A1 Jirasiritham, Sopon
A1 Janphram, Chitimaporn
A1 Tossiri, Sansanee
A1 Upama, Supparat
A1 Sethaudom, Chavachol
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260694.abstract
AB We presented an initial pilot study report focused on immunogenicity and safety following an inactivated whole-virus severe acute respiratory syndrome coronavirus 2 vaccination among kidney transplant (KT) recipients. At four weeks after the first dose of vaccine, the level of anti–receptor-binding domain IgG antibody was not significantly different compared to before vaccination in 30 KT recipients (p = 0.45). Moreover, a significant lower mean (95% CI) anti–receptor-binding domain IgG antibody was observed compared to 30 immunocompetent controls (2.4 [95% CI 1.3-3.5] vs. 173.1 [95% CI 88.3-2,457.9] AU/mL, p < 0.001). Mild adverse events included fever (17%) and localized pain at the injection site (14%) were observed after vaccination.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThai Clinical Trials Registry, TCTR20210226002Funding StatementThis study received a grant from the National Research Council of Thailand (NRCT), Ministry of Higher Education, Science, Research, and Innovation of Thailand in collaboration with the Department of Medical Services, Ministry of Public Health of Thailand (102912). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Faculty of Medicine reviewed and approved the study protocol at Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (approval number: MURA2021/242). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data referred to in the manuscript is available upon request.